SynthesisScientific reports2025
Comparison between long-acting pegylated and daily recombinant human growth hormone for pediatric growth hormone deficiency a systematic review.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Analysis of differences in response to long-acting growth hormone therapy and influencing factors between patients with idiopathic short stature (ISS) and growth hormone deficiency (GHD).Translational pediatrics · 2026Article
- Weekly pegylated recombinant human growth hormone for prepubertal children with growth hormone deficiency: adherence advantage drives superior short-term efficacy over daily rhGH.Translational pediatrics · 2026Article
- Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients.Frontiers in pediatrics · 2026Article
- Population characteristics of children with short stature and construction of a predictive model for growth hormone treatment efficacy.Frontiers in medicine · 2026Article
- In Vitro and In Vivo Characterization of 40 kDa PEGylated Adrenomedullin in a DSS-Induced Colitis Model.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review aims to summarize the therapeutic benefits and safety profile of long-acting PEGylated recombinant human growth hormone (PEG‑rhGH) compared with daily recombinant human growth hormone (DGH) in pediatric growth hormone deficiency (PGHD) participants. We conducted an extensive literature review utilizing multiple databases, and evaluated change in height standard deviation score (∆Ht-SDS) as the primary outcome. Secondary outcomes included change in height velocity (∆HV) and incidence of total adverse events (AEs). The meta-analysis focused on comparing the standard dose of PEG‑rhGH (0.20 mg/kg/w) and DGH. The systematic review encompassed ten studies involving a total of 1,393 participants. In RCTs and cohort studies, ∆Ht-SDS at 6 months showed no significant difference between PEG-rhGH and DGH (RCTs: MD = 0.02, 95%CI: -0.02 to 0.07, p = 0.32; Cohort studies: MD = -0.02, 95%CI: -0.24 to 0.19, p = 0.82). However, PEG-rhGH had superior ∆Ht-SDS (MD = 0.19, 95%CI: 0.03 to 0.35, p = 0.02) at 12 months. Results from RCTs also showed that the incidence of total AEs was comparable for PEG-rhGH and DGH (OR = 1.12, 95%CI: 0.84 to 1.49, p = 0.45). PEG-rhGH showed superior efficacy to DGH at 12 months and comparable efficacy at other time points. The safety profiles were similar for the two treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.